4⃣ASOはドラべ症候群モデルマウスのけいれん発作を改善する https://t.co/Yem7gQJYw4 未だ治療法のないドラべ症候群に対し、核酸医薬品を用いた治療アプローチの確立を目指した論文です。最先端な創薬の世界へダイブしたい方にピッタリです! #核酸医薬品 #ASO #個別化医療
RT @Sukant_Khurana: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dr… ht…
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dr… https://t.co/ymBo52QXwk
@hcmefford: What if we could prevent the poison exon from being spliced into the transcript? Lori Isom and STOKE: Targeted augmentation of nuclear gene output (TANGO). ASO that binds to the poison exon and prevents splicing of the exon. https://t.co/pUj
RT @ShorterLab: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syn…
RT @ShorterLab: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syn…
Manuscript inspiration this week: ASOs for increased Scn1a gene expression to reverse key neurological symptoms in a mouse model of Dravet's Syndrome. https://t.co/NXNDERYrgg Strong example of systematic scientific inquiry to alleviate human suffering.
Congrats, Lori! What beautiful work!! @LoriLIsom
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome https://t.co/iOtyxR3kVt
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @JoJoYangMD: Exciting developments in treatments for Dravet syndrome, still a long way to go! #epilepsy #genetics #DravetSyndrome #Drave…
Exciting developments in treatments for Dravet syndrome, still a long way to go! #epilepsy #genetics #DravetSyndrome #Dravet #NeuroTwitter #benchtobedside
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
RT @Go3than: Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model o…
Very exciting: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome https://t.co/V9SLNbX2IL
RT @recherche_anima: Syndrome de #Dravet #épilepsie 🧠💥: un oligonucléotide antisens établit #invitro chez l'humain permet de restaurer le t…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
This collaboration between @LoriLIsom1 and #StokeTherapeutics was today’s article for @CarvillLab @alicia_guemez joint journal club presented by @pneivaschneider . Inspiring, exciting work 🤩
RT @StokeTx: Preclinical data published in @ScienceTM demonstrate the potential of Stoke’s #RNA approach as a precise, disease-modifying tr…
RT @StokeTx: Preclinical data published in @ScienceTM demonstrate the potential of Stoke’s #RNA approach as a precise, disease-modifying tr…
RT @StokeTx: Preclinical data published in @ScienceTM demonstrate the potential of Stoke’s #RNA approach as a precise, disease-modifying tr…
RT @OTSociety: #Antisense #oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a 🐀 model of Dravet syndro…
#Antisense #oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a 🐀 model of Dravet syndrome $STOK @isa_aznarez $SRPT $IONS $WVE $PRQR #NSPharma #splicemodulation @oligogirl @lab_zhou @PopplewellGroup @MayThandarAung7 h
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LalDennis: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet synd…
#Antisense oligonucleotides increase #Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of #Dravet_syndrome https://t.co/esu91AYcjV
RT @hcmefford: Congrats to @LoriLIsom1 and @StokeTx on exciting new results using an ASO to treat Dravet syndrome in mice. Beautiful work.…
Interesting approach !
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
@MCHammer Please check out the newest paper by @LoriLIsom1, her amazing lab, and @StokeTx. Preclinical data on novel treatment for #DravetSyndrome
RT @hcmefford: Congrats to @LoriLIsom1 and @StokeTx on exciting new results using an ASO to treat Dravet syndrome in mice. Beautiful work.…
RT @recherche_anima: Syndrome de #Dravet #épilepsie 🧠💥: un oligonucléotide antisens établit #invitro chez l'humain permet de restaurer le t…
Congrats to @LoriLIsom1 and @StokeTx on exciting new results using an ASO to treat Dravet syndrome in mice. Beautiful work. #epilepsy #genetics
Preclinical data published in @ScienceTM demonstrate the potential of Stoke’s #RNA approach as a precise, disease-modifying treatment for people with Dravet syndrome. https://t.co/70YYFyRb97
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Syndrome de #Dravet #épilepsie 🧠💥: un oligonucléotide antisens établit #invitro chez l'humain permet de restaurer le taux d'expression du gène codant pour le canal sodium NaV1.1 et donc de réduire la fréquence et la gravité des crises chez la #souris 🐭http
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. https://t.co/g1AozFFsKM https://t.co/FoewRnbPkA
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @stephane_auvin: Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
This is a fantastic and provides hope for other genes following in SCN1A footsteps
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Great news! Now fingers crossed for human studies
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Great work!
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome | Science Translational Medicine https://t.co/EdEtYX1s9j
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Check out the latest exciting work from @LoriLIsom1 and her talented lab 👇
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
RT @LoriLIsom1: Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression a…
Very proud of our new work in collaboration with #StokeTherapeutics! Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome https://t.co/NMSIGmfKWc
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome | Science Translational Medicine https://t.co/SS40f2UDSP